{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:46:07Z","timestamp":1791650767217,"version":"4.3.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40262-024-01370-7","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T08:01:36Z","timestamp":1712476896000},"page":"589-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review"],"prefix":"10.1007","volume":"63","author":[{"given":"J.","family":"van Gendt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Emaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Visschedijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. G.","family":"Bouwknegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-1201","authenticated-orcid":false,"given":"Paola","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,7]]},"reference":[{"issue":"8","key":"1370_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41575-023-00758-3","volume":"20","author":"MN Brondfield","year":"2023","unstructured":"Brondfield MN, Mahadevan U. Inflammatory bowel disease in pregnancy and breastfeeding. Nat Rev Gastroenterol Hepatol. 2023;20(8):504\u201323. https:\/\/doi.org\/10.1038\/s41575-023-00758-3.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1370_CR2","unstructured":"European Medicines Agency. Humira | European Medicines Agency. European Medicines Agency, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira (accessed Jul. 25, 2023)."},{"key":"1370_CR3","unstructured":"European Medicines Agency. Cimzia | European Medicines Agency. European Medicines Agency, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cimzia (accessed Jul. 25, 2023)."},{"key":"1370_CR4","unstructured":"European Medicines Agency. Simponi | European Medicines Agency. European Medicine Agency, 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/simponi (accessed Jul. 25, 2023)."},{"key":"1370_CR5","unstructured":"European Medicines Agency. Remicade | European Medicines Agency. European Medicines Agency, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remicade (accessed Jul. 25, 2023)."},{"key":"1370_CR6","unstructured":"European Medicines Agency. Soliris | European Medicines Agency. European Medicines Agency, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/soliris (accessed Jul. 25, 2023)."},{"key":"1370_CR7","unstructured":"European Medicines Agency. Tysabri | European Medicines Agency. European Medicines Agency, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tysabri (accessed Jul. 25, 2023)."},{"key":"1370_CR8","unstructured":"European Medicines Agency. RoActemra | European Medicines Agency. European Medicines Agency, 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/roactemra (accessed Jul. 25, 2023)."},{"key":"1370_CR9","unstructured":"European Medicines Agency. Entyvio | European Medicines Agency. European Medicines Agency, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/entyvio (accessed Jul. 25, 2023)."},{"key":"1370_CR10","unstructured":"European Medicines Agency. Stelara | European Medicines Agency. European Medicines Agency, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara (accessed Jul. 25, 2023)."},{"issue":"3","key":"1370_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286\u201392. https:\/\/doi.org\/10.1016\/j.cgh.2012.11.011.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1370_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/cpt.1827","volume":"108","author":"GAM Eliesen","year":"2020","unstructured":"Eliesen GAM, et al. Assessment of placental disposition of infliximab and etanercept in women with autoimmune diseases and in the ex vivo perfused placenta. Clin Pharmacol Ther. 2020;108(1):99\u2013106. https:\/\/doi.org\/10.1002\/cpt.1827.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1370_CR13","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/rheumatology\/kez155","volume":"58","author":"Y Tada","year":"2019","unstructured":"Tada Y, Sakai M, Nakao Y, Maruyama A, Ono N, Koarada S. Placental transfer of tocilizumab in a patient with rheumatoid arthritis. Rheumatology (United Kingdom). 2019;58(9):1694\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kez155. (Rheumatology (Oxford)).","journal-title":"Rheumatology (United Kingdom)"},{"issue":"10","key":"1370_CR14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.cgh.2006.07.018","volume":"4","author":"EA Vasiliauskas","year":"2006","unstructured":"Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4(10):1255\u20138. https:\/\/doi.org\/10.1016\/j.cgh.2006.07.018.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"1370_CR15","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1177\/106002808301701124","volume":"17","author":"GG Briggs","year":"1983","unstructured":"Briggs GG, Freeman RK, Tower. Book review: drugs in pregnancy and lactation. A reference guide to fetal and neonatal risk. Drug Intell Clin Pharm. 1983;17(11):852\u2013852. https:\/\/doi.org\/10.1177\/106002808301701124.","journal-title":"Drug Intell Clin Pharm"},{"issue":"1","key":"1370_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.378","volume":"100","author":"A Saint-Raymond","year":"2016","unstructured":"Saint-Raymond A, De Vries CS. Medicine safety in pregnancy and ambitions for the EU medicine regulatory framework. Clin Pharmacol Ther. 2016;100(1):21\u20133. https:\/\/doi.org\/10.1002\/cpt.378.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1370_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cpt.380","volume":"100","author":"L Sahin","year":"2016","unstructured":"Sahin L, Nallani SC, Tassinari MS. Medication use in pregnancy and the pregnancy and lactation labeling rule. Clin Pharmacol Ther. 2016;100(1):23\u20135. https:\/\/doi.org\/10.1002\/cpt.380.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1370_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.381","volume":"100","author":"JM Korth-Bradley","year":"2016","unstructured":"Korth-Bradley JM. Industry perspective of drug development for pregnant\/breastfeeding women. Clin Pharmacol Ther. 2016;100(1):19\u201321. https:\/\/doi.org\/10.1002\/cpt.381.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1370_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388. https:\/\/doi.org\/10.1002\/psp4.12224.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"12","key":"1370_CR20","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s11095-017-2259-3","volume":"34","author":"P Malik","year":"2017","unstructured":"Malik P, Phipps C, Edginton A, Blay J. Pharmacokinetic considerations for antibody-drug conjugates against cancer. Pharm Res. 2017;34(12):2579\u201395. https:\/\/doi.org\/10.1007\/s11095-017-2259-3.","journal-title":"Pharm Res"},{"issue":"11","key":"1370_CR21","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40262-017-0539-z","volume":"56","author":"A Dallmann","year":"2017","unstructured":"Dallmann A, Ince I, Meyer M, Willmann S, Eissing T, Hempel G. Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy. Clin Pharmacokinet. 2017;56(11):1303\u201330. https:\/\/doi.org\/10.1007\/s40262-017-0539-z.","journal-title":"Clin Pharmacokinet"},{"key":"1370_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109914","volume":"117","author":"MA Tegenge","year":"2023","unstructured":"Tegenge MA, Mahmood I, Struble EB, Sauna Z. Pharmacokinetics of antibodies during pregnancy General pharmacokinetics and pregnancy related physiological changes (Part 1). Int Immunopharmacol. 2023;117: 109914. https:\/\/doi.org\/10.1016\/j.intimp.2023.109914.","journal-title":"Int Immunopharmacol"},{"key":"1370_CR23","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-022-00722-0","author":"KL Gill","year":"2022","unstructured":"Gill KL, Jones HM. Opportunities and challenges for PBPK model of mAbs in paediatrics and pregnancy. AAPS J. 2022. https:\/\/doi.org\/10.1208\/s12248-022-00722-0.","journal-title":"AAPS J"},{"issue":"29","key":"1370_CR24","doi-asserted-by":"publisher","first-page":"E1129","DOI":"10.1503\/cmaj.202391","volume":"193","author":"A Pham-Huy","year":"2021","unstructured":"Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Cha\u00e2r DM. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ. 2021;193(29):E1129\u201336. https:\/\/doi.org\/10.1503\/cmaj.202391.","journal-title":"CMAJ"},{"key":"1370_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","volume":"116","author":"C Porter","year":"2016","unstructured":"Porter C, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7\u201312. https:\/\/doi.org\/10.1016\/j.jri.2016.04.284.","journal-title":"J Reprod Immunol"},{"issue":"48","key":"1370_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2107269118","volume":"118","author":"AQ Bartlett","year":"2021","unstructured":"Bartlett AQ, et al. Pregnancy and weaning regulate human maternal liver size and function. Proc Natl Acad Sci USA. 2021;118(48):1\u201310. https:\/\/doi.org\/10.1073\/pnas.2107269118.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1370_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/ejcn.2014.40","volume":"68","author":"EM Widen","year":"2014","unstructured":"Widen EM, Gallagher D. Body composition changes in pregnancy: measurement, predictors and outcomes. Eur J Clin Nutr. 2014;68(6):643\u201352. https:\/\/doi.org\/10.1038\/ejcn.2014.40.","journal-title":"Eur J Clin Nutr"},{"issue":"5","key":"1370_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/1381612825666190320135137","volume":"25","author":"A Dallmann","year":"2019","unstructured":"Dallmann A, Mian P, Van den Anker J, Allegaert K. Clinical pharmacokinetic studies in pregnant women and the relevance of pharmacometric tools. Curr Pharm Des. 2019;25(5):483\u201395. https:\/\/doi.org\/10.2174\/1381612825666190320135137.","journal-title":"Curr Pharm Des"},{"issue":"10","key":"1370_CR29","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/apt.14040","volume":"45","author":"CH Seow","year":"2017","unstructured":"Seow CH, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1329\u201338. https:\/\/doi.org\/10.1111\/apt.14040.","journal-title":"Aliment Pharmacol Ther"},{"key":"1370_CR30","unstructured":"\u201cPRISMA.\u201d https:\/\/prisma-statement.org\/prismastatement\/flowdiagram.aspx (accessed Jan. 13, 2023)."},{"key":"1370_CR31","unstructured":"CGB-MED. geneesmiddeleninformatiebank | metadata. CBG, 2023. https:\/\/www.cbg-meb.nl\/."},{"key":"1370_CR32","unstructured":"World Health Organization. Collaborating Centre for Drug Statistics Methodology. WHOCC - ATC\/DDD Index. 2019. https:\/\/www.whocc.no\/atc_ddd_index\/?code=L04AB (accessed Jul. 25, 2023)."},{"issue":"8","key":"1370_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3109\/00365521.2013.812141","volume":"48","author":"M Bortlik","year":"2013","unstructured":"Bortlik M, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48(8):951\u20138. https:\/\/doi.org\/10.3109\/00365521.2013.812141.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"1370_CR34","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.crohns.2012.10.009","volume":"7","author":"M Julsgaard","year":"2013","unstructured":"Julsgaard M, Brown S, Gibson P, Bell S. Adalimumab levels in an infant. J Crohns Colitis. 2013;7(7):597\u20138. https:\/\/doi.org\/10.1016\/j.crohns.2012.10.009.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1370_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","volume":"151","author":"M Julsgaard","year":"2016","unstructured":"Julsgaard M, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2016.04.002.","journal-title":"Gastroenterology"},{"issue":"10","key":"1370_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/apt.16102","volume":"52","author":"E Flanagan","year":"2020","unstructured":"Flanagan E, et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(10):1551\u201362. https:\/\/doi.org\/10.1111\/apt.16102.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1370_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.7326\/L17-0629","volume":"169","author":"R Labetoulle","year":"2018","unstructured":"Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. Ann Intern Med. 2018;169(1):60\u20131. https:\/\/doi.org\/10.7326\/L17-0629.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1370_CR38","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/ecco-jcc\/jjy058","volume":"12","author":"SL Kanis","year":"2018","unstructured":"Kanis SL, De Lima-Karagiannis A, Van Der Ent C, Rizopoulos D, Van Der Woude CJ. Anti-TNF levels in cord blood at birth are associated with anti-TNF type. J Crohn\u2019s Colitis. 2018;12(8):839\u2013947. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy058.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"1370_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/03009742.2019.1639821","volume":"49","author":"M Moriyama","year":"2020","unstructured":"Moriyama M, Wada Y, Minamoto T, Kondo M, Honda M, Murakawa Y. Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report. Scand J Rheumatol. 2020;49(2):165\u20136. https:\/\/doi.org\/10.1080\/03009742.2019.1639821.","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"1370_CR40","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1136\/annrheumdis-2017-212366","volume":"77","author":"T Morita","year":"2018","unstructured":"Morita T, Fujimoto K, Shima Y, Ogata A, Kumanogoh A. Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis. Ann Rheum Dis. 2018;77(9):2017\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212366.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1370_CR41","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.491","volume":"55","author":"JR Wade","year":"2015","unstructured":"Wade JR, et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn\u2019s disease. J Clin Pharmacol. 2015;55(8):866\u201374. https:\/\/doi.org\/10.1002\/jcph.491.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1370_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/ecco-jcc\/jjy192","volume":"13","author":"L Benoit","year":"2019","unstructured":"Benoit L, Mir O, Berveiller P. Treating ulcerative colitis during pregnancy: evidence of materno-fetal transfer of golimumab. J Crohn\u2019s Colitis. 2019;13(5):669\u201370. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy192.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"1370_CR43","first-page":"64","volume":"10","author":"S Kane","year":"2009","unstructured":"Kane S, Ford J, Cohen R. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn\u2019s disease before and after delivery: commentary. Inflamm Bowel Dis Monit. 2009;10(2):64.","journal-title":"Inflamm. Bowel Dis. Monit."},{"issue":"1","key":"1370_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/2050640620964619","volume":"9","author":"AM Gri\u0161i\u0107","year":"2021","unstructured":"Gri\u0161i\u0107 AM, et al. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United Eur Gastroenterol J. 2021;9(1):91\u2013101. https:\/\/doi.org\/10.1177\/2050640620964619.","journal-title":"United Eur Gastroenterol J"},{"issue":"9","key":"1370_CR45","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/ecco-jcc\/jjx034","volume":"11","author":"T Vestergaard","year":"2017","unstructured":"Vestergaard T, Kammerlander H, Brock B, Julsgaard M. Immunoglobulin and infliximab concentrations in dichorionic twins exposed to infliximab in utero. J Crohn\u2019s Colitis. 2017;11(9):1152\u20133. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx034. (Oxford Academic).","journal-title":"J Crohn\u2019s Colitis"},{"issue":"4","key":"1370_CR46","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","volume":"160","author":"U Mahadevan","year":"2021","unstructured":"Mahadevan U, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160(4):1131\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.038.","journal-title":"Gastroenterology"},{"issue":"3","key":"1370_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.crohns.2011.10.002","volume":"6","author":"C Steenholdt","year":"2012","unstructured":"Steenholdt C, Al-Khalaf M, Ainsworth MA, Brynskov J. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohn\u2019s Colitis. 2012;6(3):358\u201361. https:\/\/doi.org\/10.1016\/j.crohns.2011.10.002.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2","key":"1370_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/aji.13559","volume":"88","author":"RM Burwick","year":"2022","unstructured":"Burwick RM, et al. Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: a case series. Am J Reprod Immunol. 2022;88(2):4\u201311. https:\/\/doi.org\/10.1111\/aji.13559.","journal-title":"Am J Reprod Immunol"},{"issue":"4","key":"1370_CR49","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.kint.2019.01.012","volume":"95","author":"C Duineveld","year":"2019","unstructured":"Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, van de Kar NCAJ, Wetzels JFM. Placental passage of eculizumab and complement blockade in a newborn. Kidney Int. 2019;95(4):996. https:\/\/doi.org\/10.1016\/j.kint.2019.01.012. (Elsevier B.V.).","journal-title":"Kidney Int"},{"issue":"11","key":"1370_CR50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/MD.0000000000006338","volume":"96","author":"A Gustavsen","year":"2017","unstructured":"Gustavsen A, et al. Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome. Medicine (United States). 2017;96(11):2\u20135. https:\/\/doi.org\/10.1097\/MD.0000000000006338.","journal-title":"Medicine (United States)"},{"issue":"1","key":"1370_CR51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.lrr.2015.05.001","volume":"4","author":"R Sharma","year":"2015","unstructured":"Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Reports. 2015;4(1):36\u20138. https:\/\/doi.org\/10.1016\/j.lrr.2015.05.001.","journal-title":"Leuk Res Reports"},{"issue":"12","key":"1370_CR52","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","volume":"31","author":"A Servais","year":"2016","unstructured":"Servais A, et al. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2016;31(12):2122\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfw314.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1370_CR53","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/13524585211052168","volume":"28","author":"AA Toorop","year":"2022","unstructured":"Toorop AA, et al. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis. Mult Scler J. 2022;28(2):323\u20136. https:\/\/doi.org\/10.1177\/13524585211052168.","journal-title":"Mult Scler J"},{"issue":"August","key":"1370_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.715195","volume":"12","author":"U Proschmann","year":"2021","unstructured":"Proschmann U, Haase R, Inojosa H, Akg\u00fcn K, Ziemssen T. Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to natalizumab during pregnancy and lactation. Front Immunol. 2021;12(August):1\u201310. https:\/\/doi.org\/10.3389\/fimmu.2021.715195.","journal-title":"Front Immunol"},{"issue":"3","key":"1370_CR55","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/apt.14837","volume":"48","author":"M Julsgaard","year":"2018","unstructured":"Julsgaard M, Kjeldsen J, Brock B, Baumgart DC. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. Aliment Pharmacol Ther. 2018;48(3):386\u20138. https:\/\/doi.org\/10.1111\/apt.14837.","journal-title":"Aliment Pharmacol Ther"},{"key":"1370_CR56","doi-asserted-by":"crossref","unstructured":"Prentice R, Flanagan E and Wright EK. Changes over time in the L\u00e9mann Index and the Inflammatory Bowel Disease-Disability Index in patients with Crohn\u2019s disease. J Crohn's  Colitis  2023;10:508\u2013510","DOI":"10.1093\/ecco-jcc\/jjac190.0508"},{"issue":"11\u201312","key":"1370_CR57","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/apt.15027","volume":"48","author":"E Flanagan","year":"2018","unstructured":"Flanagan E, et al. Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. Aliment Pharmacol Ther. 2018;48(11\u201312):1328\u201330. https:\/\/doi.org\/10.1111\/apt.15027.","journal-title":"Aliment Pharmacol Ther"},{"key":"1370_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/17562848211032790","author":"K Mitrova","year":"2021","unstructured":"Mitrova K, et al. Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. Therap Adv Gastroenterol. 2021. https:\/\/doi.org\/10.1177\/17562848211032790.","journal-title":"Therap Adv Gastroenterol."},{"issue":"12","key":"1370_CR59","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","volume":"16","author":"K Mitrova","year":"2022","unstructured":"Mitrova K, et al. Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study. J Crohns Colitis. 2022;16(12):1808\u201315. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac086.","journal-title":"J Crohns Colitis"},{"key":"1370_CR60","doi-asserted-by":"publisher","first-page":"E229","DOI":"10.1093\/rheumatology\/keac177","volume":"61","author":"E Weber","year":"2022","unstructured":"Weber E, Millet A. Letter to the editor (case report). Rheumatol (United Kingdom). 2022;61:E229-e231. https:\/\/doi.org\/10.1093\/rheumatology\/keac177.","journal-title":"Rheumatol. (United Kingdom)"},{"issue":"10","key":"1370_CR61","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1016\/j.jaip.2020.05.054","volume":"8","author":"J Saito","year":"2020","unstructured":"Saito J, et al. Omalizumab concentrations in pregnancy and lactation: a case study. J Allergy Clin Immunol Pract. 2020;8(10):3603\u20134. https:\/\/doi.org\/10.1016\/j.jaip.2020.05.054.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"1370_CR62","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/rheumatology\/key091","volume":"57","author":"J Saito","year":"2018","unstructured":"Saito J, et al. Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study. Rheumatol (United Kingdom). 2018;57(8):1499\u2013500. https:\/\/doi.org\/10.1093\/rheumatology\/key091.","journal-title":"Rheumatol. (United Kingdom)"},{"issue":"6","key":"1370_CR63","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/1756-185X.13557","volume":"22","author":"J Saito","year":"2019","unstructured":"Saito J, et al. Clinical application of the dried milk spot method for measuring tocilizumab concentrations in the breast milk of patients with rheumatoid arthritis. Int J Rheum Dis. 2019;22(6):1130\u20137. https:\/\/doi.org\/10.1111\/1756-185X.13557.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"1370_CR64","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/1753495X20966094","volume":"14","author":"J Saito","year":"2020","unstructured":"Saito J, et al. Tocilizumab drug levels during pregnancy and lactation: a woman who discontinued tocilizumab therapy until the end of the first trimester and resumed it after birth. Obstet Med. 2020;14(4):260\u20132. https:\/\/doi.org\/10.1177\/1753495X20966094.","journal-title":"Obstet Med"},{"issue":"4","key":"1370_CR65","doi-asserted-by":"publisher","first-page":"426","DOI":"10.23922\/jarc.2021-021","volume":"5","author":"M Sako","year":"2021","unstructured":"Sako M, et al. Safety prediction of infants born to mothers with Crohn\u2019s disease treated with biological agents in the late gestation period. J Anus Rectum Colon. 2021;5(4):426\u201332. https:\/\/doi.org\/10.23922\/jarc.2021-021.","journal-title":"J Anus Rectum Colon"},{"issue":"1","key":"1370_CR66","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40780-022-00249-8","volume":"8","author":"J Saito","year":"2022","unstructured":"Saito J, et al. Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum. J Pharm Heal Care Sci. 2022;8(1):18. https:\/\/doi.org\/10.1186\/s40780-022-00249-8.","journal-title":"J Pharm Heal Care Sci"},{"issue":"6","key":"1370_CR67","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/apt.16739","volume":"55","author":"E Flanagan","year":"2022","unstructured":"Flanagan E, et al. Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Aliment Pharmacol Ther. 2022;55(6):700\u20134. https:\/\/doi.org\/10.1111\/apt.16739.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1370_CR68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ecco-jcc\/jjy153","volume":"13","author":"E Klenske","year":"2019","unstructured":"Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R. Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn\u2019s disease. J Crohn\u2019s Colitis. 2019;13(2):267\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy153.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"3","key":"1370_CR69","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/ecco-jcc\/jjx141","volume":"12","author":"CR Rowan","year":"2018","unstructured":"Rowan CR, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn\u2019s disease treated until 33 weeks of gestation. J Crohn\u2019s Colitis. 2018;12(3):376\u20138. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx141.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"6","key":"1370_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10061242","volume":"10","author":"S Restellini","year":"2021","unstructured":"Restellini S, Afif W. Update on tdm (Therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease. J Clin Med. 2021;10(6):1\u201316. https:\/\/doi.org\/10.3390\/jcm10061242.","journal-title":"J Clin Med"},{"issue":"6","key":"1370_CR71","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/cpt.3031","volume":"114","author":"J Chen","year":"2023","unstructured":"Chen J, et al. Physiologically-based pharmacokinetic modeling of anti-tumor necrosis factor agents for inflammatory bowel disease patients to predict the withdrawal time in pregnancy and vaccine time in infants. Clin Pharmacol Ther. 2023;114(6):1254\u201363. https:\/\/doi.org\/10.1002\/cpt.3031.","journal-title":"Clin Pharmacol Ther"},{"key":"1370_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14565","author":"GAM Eliesen","year":"2020","unstructured":"Eliesen GAM, et al. Placental disposition of eculizumab, C5 and C5-eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria. Br J Clin Pharma. 2020. https:\/\/doi.org\/10.1111\/bcp.14565.","journal-title":"Br J Clin Pharma"},{"issue":"8","key":"1370_CR73","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1177\/1352458511401944","volume":"17","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler J. 2011;17(8):958\u201363. https:\/\/doi.org\/10.1177\/1352458511401944.","journal-title":"Mult Scler J"},{"issue":"Supplement_1","key":"1370_CR74","doi-asserted-by":"publisher","first-page":"S460","DOI":"10.1093\/ecco-jcc\/jjz203.666","volume":"14","author":"A Geldhof","year":"2020","unstructured":"Geldhof A, Volger S, Lin CB, O\u2019Brien C, Tikhonov I. P538 Pregnancy outcomes in women with psoriasis, psoriatic arthritis, Crohn\u2019s disease and ulcerative colitis treated with ustekinumab. J Crohn\u2019s Colitis. 2020;14(Supplement_1):S460\u2013S460. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz203.666.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"2_suppl","key":"1370_CR75","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/1352458519869496","volume":"25","author":"D Landi","year":"2019","unstructured":"Landi D, et al. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Mult Scler J. 2019;25(2_suppl):892\u2013994. https:\/\/doi.org\/10.1177\/1352458519869496.","journal-title":"Mult Scler J"},{"issue":"2","key":"1370_CR76","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228\u201333. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212196.","journal-title":"Ann Rheum Dis"},{"key":"1370_CR77","unstructured":"SHIKARI Q-INFLIXI - Infliximab (Remicade\u00ae) (quantitative). https:\/\/www.iwai-chem.net\/elisa-kit\/shikari-q-inflixi-infliximab-remicade-quantitative\/ (accessed Feb. 15, 2023)."},{"key":"1370_CR78","unstructured":"How They Work \u2013 Prometheus Laboratories. https:\/\/www.prometheuslabs.com\/anser\/how-they-work\/ (accessed Feb. 15, 2023)."},{"issue":"1","key":"1370_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0635-2","volume":"13","author":"T Sehr","year":"2016","unstructured":"Sehr T, et al. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. J Neuroinflammation. 2016;13(1):1\u201311. https:\/\/doi.org\/10.1186\/s12974-016-0635-2.","journal-title":"J Neuroinflammation"},{"key":"1370_CR80","unstructured":"Elisa T. Tocilizumab ELISA (mAb-based). 2020."},{"key":"1370_CR81","unstructured":"Elisa U. Ustekinumab ELISA (mAb-based). 2017; no. 022, p. 1\u20137."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01370-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01370-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01370-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T13:13:48Z","timestamp":1716210828000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01370-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,7]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1370"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01370-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,7]]},"assertion":[{"value":"12 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors. Competing interests: Jip van Gendt, Robin Emaus, Marijn C. Visschedijk, Dianne Bouwknegt, Karina de Leeuw, Jelmer R. Prins, and Paola Mian declare that they have no financial or non-financial interests that are directly or indirectly related to the work submitted for publication. Daan J. Touw is vice chair of the Medical Advisory Board of Sanquin. Paul Malik is a full-time employee of Calico Life Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JvG and RE contributed to the literature search, data extraction, data analysis, and writing the initial draft of the manuscript. MCV, JRP, and DJT contributed to the conceptualization of the study and reviewing the manuscript. DB and KdL contributed to reviewing the manuscript. PMa contributed to the conceptualization of the study and writing and reviewing the manuscript. PMi contributed to the conceptualization of the study, literature search, data extraction, data analysis, and writing and reviewing the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}